{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:48:32Z","timestamp":1792756112925,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1136\/ijgc-2024-005484","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T23:00:13Z","timestamp":1727305213000},"page":"101852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient\/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO\/GOG3031\/RUBY trial"],"prefix":"10.1016","volume":"35","clinical-trial-number":[{"clinical-trial-number":"nct03981796","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03981796","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03981796","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03981796","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5444-6305","authenticated-orcid":false,"given":"Giorgio","family":"Valabrega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakari","family":"Hietanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirwen M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1346-8134","authenticated-orcid":false,"given":"Dominik","family":"Denschlag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tashanna","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Thijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn P.","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksandr","family":"Zub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Landrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2823-7590","authenticated-orcid":false,"given":"Beyhan","family":"Ataseven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Gogoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Podzielinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle","family":"Cloven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6985-0159","authenticated-orcid":false,"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarshan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Stuckey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4578-2061","authenticated-orcid":false,"given":"Bhavana","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeles Alvarez","family":"Secord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Chase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Garside","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor Raza","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Destin","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2024-005484_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2024-005484_bib2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2021.01.036","article-title":"Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019","volume":"161","author":"Gu","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005484_bib3","unstructured":"International Agency for Research on Cancer. Cancer tomorrow. Available: https:\/\/gco.iarc.fr\/tomorrow\/en\/dataviz\/isotype?cancers=24&single_unit=50000 [Accessed Aug 2023]."},{"key":"10.1136\/ijgc-2024-005484_bib4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/GCO.0000000000000855","article-title":"Treatment options for molecular subtypes of endometrial cancer in 2023","volume":"35","author":"Karpel","year":"2023","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1136\/ijgc-2024-005484_bib5","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005484_bib6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2024-005484_bib7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1136\/ijgc-2024-005484_bib8","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial","volume":"6","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2024-005484_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003777","volume":"10","author":"Oaknin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1136\/ijgc-2024-005484_bib10","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005484_bib11","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2024-005484_bib16","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.31557\/APJCP.2020.21.7.1969","article-title":"Quality of life in patients with gynecological cancers: a web-based study","volume":"21","author":"Shirali","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1136\/ijgc-2024-005484_bib17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ygyno.2019.11.033","article-title":"Changes in health-related quality of life in older women after diagnosis with gynecologic cancer","volume":"156","author":"Klapheke","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005484_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s40425-019-0594-0","article-title":"The promise of immuno-oncology: implications for defining the value of cancer treatment","volume":"7","author":"Kaufman","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1136\/ijgc-2024-005484_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.779915","article-title":"Advances in knowledge and management of immune-related adverse events in cancer immunotherapy","volume":"13","author":"Olsen","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1136\/ijgc-2024-005484_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1136\/ijgc-2024-005484_bib21","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","article-title":"The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline","volume":"33","author":"Di Maio","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005484_bib22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1200\/EDBK_200383","article-title":"Implementation of patient-reported outcomes in routine medical care","volume":"38","author":"Basch","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1136\/ijgc-2024-005484_bib25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ygyno.2022.06.005","article-title":"Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high\/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study","volume":"166","author":"O\u2019Malley","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005484_bib26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejca.2023.03.015","article-title":"Health-related quality of life in patients with advanced endometrial cancer treated wth lenvatinib plus pembrolizumab or treatment of physician\u2019s choice","volume":"186","author":"Lorusso","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2024-005484_bib27","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1136\/ijgc-2022-003492","article-title":"Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient\/microsatellite instability-high endometrial cancer treated with dostarlimab","volume":"32","author":"Kristeleit","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005484_bib28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2024-005484_bib29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejca.2010.08.014","article-title":"Psychometric validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24)","volume":"47","author":"Greimel","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2024-005484_bib30","series-title":"The EORTC QLQ-C30 scoring manual","author":"Fayers","year":"2001"},{"key":"10.1136\/ijgc-2024-005484_bib31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005484_bib32","series-title":"Quality of Life: Assessment, Analysis and Interpretation","article-title":"Chapter 15: missing data","author":"Fayers","year":"2016"},{"key":"10.1136\/ijgc-2024-005484_bib33","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.3390\/curroncol29080414","article-title":"Evaluation of patient-reported symptoms and functioning after treatment for endometrial cancer","volume":"29","author":"Sobo\u010dan","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1136\/ijgc-2024-005484_bib34","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1097\/IGC.0000000000000299","article-title":"Quality of life and patient-reported outcomes in endometrial cancer clinical trials: a call for action","volume":"24","author":"Joly","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005484_bib35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ygyno.2021.10.084","article-title":"Initial findings from a prospective, large scale patient reported outcomes program in patients with gynecologic malignancy","volume":"164","author":"Sisodia","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005484_bib36","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/bjs\/znad022","article-title":"Oncological surgery follow-up and quality of life: meta-analysis","volume":"110","author":"Wullaert","year":"2023","journal-title":"Br J Surg"},{"key":"10.1136\/ijgc-2024-005484_bib37","first-page":"5943","article-title":"Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy","volume":"28","author":"Hirose","year":"2020","journal-title":"Support Care Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25009715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25009715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2024-005484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T04:34:29Z","timestamp":1762835669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25009715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1048891X25009715"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2024-005484","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient\/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO\/GOG3031\/RUBY trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2024-005484","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"101852"}}